AR055336A1 - Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso - Google Patents

Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso

Info

Publication number
AR055336A1
AR055336A1 ARP060102533A ARP060102533A AR055336A1 AR 055336 A1 AR055336 A1 AR 055336A1 AR P060102533 A ARP060102533 A AR P060102533A AR P060102533 A ARP060102533 A AR P060102533A AR 055336 A1 AR055336 A1 AR 055336A1
Authority
AR
Argentina
Prior art keywords
powder
tigecycline
tigecicline
solution
production
Prior art date
Application number
ARP060102533A
Other languages
English (en)
Spanish (es)
Inventor
Gurmukh Chanana
Dominique Ventura
Richard Saunders
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR055336A1 publication Critical patent/AR055336A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/22Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/40Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/461,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ARP060102533A 2005-06-16 2006-06-15 Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso AR055336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69117305P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
AR055336A1 true AR055336A1 (es) 2007-08-22

Family

ID=37111782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102533A AR055336A1 (es) 2005-06-16 2006-06-15 Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso

Country Status (22)

Country Link
US (1) US7705168B2 (https=)
EP (1) EP1898884A2 (https=)
JP (3) JP2008543871A (https=)
KR (1) KR20080024201A (https=)
CN (1) CN101198315A (https=)
AR (1) AR055336A1 (https=)
AU (1) AU2006261636A1 (https=)
BR (1) BRPI0612228A2 (https=)
CA (1) CA2610909A1 (https=)
CR (1) CR9594A (https=)
EC (1) ECSP078005A (https=)
GT (1) GT200600259A (https=)
IL (1) IL187979A0 (https=)
MX (1) MX2007015960A (https=)
NO (1) NO20076264L (https=)
PA (1) PA8680201A1 (https=)
PE (1) PE20070072A1 (https=)
RU (1) RU2007145595A (https=)
SV (1) SV2007002575A (https=)
TW (1) TW200716203A (https=)
WO (1) WO2006138641A2 (https=)
ZA (1) ZA200710906B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244335A1 (en) * 2006-04-17 2007-10-18 Teva Pharmaceutical Industries Ltd. Isolation of tetracycline derivatives
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
ES2622356T3 (es) * 2006-04-24 2017-07-06 Teva Pharmaceutical Industries, Ltd. Formas cristalinas de tigeciclina y procesos para su preparación
MX2008009520A (es) * 2006-11-29 2009-02-26 Teva Pharma Formas cristalinas de tigeciclina y procesos de preparacion de ellas.
MX2008009727A (es) * 2006-11-30 2009-01-09 Teva Pharma Procesos para la preparacion de 9-haloacetamidominociclinas.
US20080214869A1 (en) * 2007-03-01 2008-09-04 Sergei Fine Processes for purification of tigecycline
WO2009052152A2 (en) * 2007-10-16 2009-04-23 Wyeth Tigecycline and methods of preparing intermediates
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
WO2010017273A2 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
PT104350A (pt) 2009-01-23 2010-07-23 Hovione Farmaci Ncia S A Processo de isolamento de tigeciclina
CA2751238A1 (en) 2009-03-12 2010-10-07 Wyeth Llc Nitration of tetracyclines
CN103417498B (zh) * 2012-05-18 2017-09-12 山东新时代药业有限公司 一种替加环素冻干粉针剂的制备方法
IN2013MU01127A (https=) 2013-03-26 2015-05-01 Astron Res Ltd
WO2014167575A2 (en) 2013-03-26 2014-10-16 Astron Research Limited Stable tigecycline composition
CN103202814A (zh) * 2013-04-23 2013-07-17 成都百裕科技制药有限公司 一种注射用替加环素的制备方法
CN105924367B (zh) * 2016-04-18 2017-12-29 镇江高海生物药业有限公司 多西环素一水物的有关物质及其分析检测方法
US20190233153A1 (en) * 2018-01-26 2019-08-01 AL Pharma, Inc. Manufacturing and packaging of a sterile drug product
CN108653216B (zh) * 2018-05-28 2020-12-18 福安药业集团湖北人民制药有限公司 注射用替加环素
WO2021063468A1 (en) 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof
CN116531322A (zh) * 2023-06-27 2023-08-04 遂成药业股份有限公司 一种高稳定性呋塞米注射液及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026248A (en) 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5675030A (en) 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
ATE415973T1 (de) * 2004-10-28 2008-12-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
EP1858488B2 (en) * 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
AR057034A1 (es) 2005-05-27 2007-11-14 Wyeth Corp Metodos para purificar tigeciclina

Also Published As

Publication number Publication date
JP2009191083A (ja) 2009-08-27
CN101198315A (zh) 2008-06-11
PE20070072A1 (es) 2007-02-25
AU2006261636A1 (en) 2006-12-28
IL187979A0 (en) 2008-03-20
PA8680201A1 (es) 2007-01-17
KR20080024201A (ko) 2008-03-17
GT200600259A (es) 2007-05-08
WO2006138641A3 (en) 2007-05-18
WO2006138641A2 (en) 2006-12-28
RU2007145595A (ru) 2009-07-27
TW200716203A (en) 2007-05-01
CA2610909A1 (en) 2006-12-28
JP2010024252A (ja) 2010-02-04
CR9594A (es) 2008-03-07
SV2007002575A (es) 2007-01-03
JP2008543871A (ja) 2008-12-04
US20070026080A1 (en) 2007-02-01
NO20076264L (no) 2008-03-10
MX2007015960A (es) 2008-03-06
EP1898884A2 (en) 2008-03-19
ECSP078005A (es) 2008-01-23
US7705168B2 (en) 2010-04-27
ZA200710906B (en) 2009-03-25
BRPI0612228A2 (pt) 2011-03-29

Similar Documents

Publication Publication Date Title
AR055336A1 (es) Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso
EP3150559B1 (en) Antibacterial water
JP2008543871A5 (https=)
FI4011377T3 (fi) Suonensisäinen infuusioannosmuoto sisältäen pemetreksediä
DE60309731D1 (de) Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
NZ523458A (en) New method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
WO2012121523A3 (en) Process for preparing pharmaceutical formulation in form of antioxidant-free solution for injection containing pemetrexed or its salt
US20150190509A1 (en) Resiniferatoxin solution
RU2011140749A (ru) Устройство для интраназального введения
JP6244608B2 (ja) 水素含有エアゾールおよび該水素含有エアゾールの保管方法
EP2920106B1 (en) A method for filling bottles
CN104136017A (zh) 眼科用组合物
EA201171440A1 (ru) Способ ароматизации размещаемого в упаковке пищевого продукта
NO20061382L (no) Drikke og naeringsmidler som er motstandsdyktige mot lys-induserte smaksforandringer, fremgangsmater for a fremstille samme, og materialer for a bevirke slik modsdyktighet
ES2445871T3 (es) Procedimiento para el almacenamiento y para el transporte de diésteres cíclicos
AR124867A1 (es) Un medicamento en una bolsa de goteo intravenoso plegable lista para usar herméticamente sellada, método para hacer dicho medicamento y medicamento elaborado mediante dicho método
JP6120766B2 (ja) 注射液製剤及びその製造方法
JP6150703B2 (ja) ピタバスタチンカルシウム塩の分解抑制方法
GR1010637B (el) Σταθερο υδατικο διαλυμα παρακεταμολης για χρηση σε ενδοφλεβια εγχυση
ME01745B (me) NOVA STABILNA HIPERBARIČNA KOMPOZICIJA KOJA SADRŽI PRILOKAIN HCL,PRIMENA NAVEDENE NOVE KOMPOZICIJE ZA INTRATEKALNU ANESTEZIJU l POSTUPAK ZA PROIZVODNJU NAVEDENE KOMPOZICIJE
RU2017146440A (ru) Способ получения лекарственного средства на основе олигопептида аллоферона-1, имеющего противовирусную и иммуномодулирующую направленность и лекарственное средство увеличенного срока хранения, полученное с его помощью
AU2006203741A1 (en) Method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
Tóth Methadone overdose Fatal toxicity: case report
MX2008009272A (en) Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
TH11930C3 (th) เครื่องดื่มน้ำเมล่อนผสมสับปะรด

Legal Events

Date Code Title Description
FB Suspension of granting procedure